vTv Therapeutics (VTVT) Fundamental Analysis: Revenue, Earnings & Valuation

4.13 / 10

Netural

Fundamental score is 4.13 (Neutral). Revenue‑to‑market value (+0.40 weight) and interest coverage are strengths, while Asset‑to‑market value is weak. Cost‑of‑sales ratio and inventory turnover are modest. Overall, fundamentals are average with limited upside potential.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight42.73%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.59%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.87%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value26.08

Score3/3

Weight7.94%

1M Return1.67%

PB-ROE

Value0.35

Score2/3

Weight39.86%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.23

Score3/3

Weight3.74%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.95%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.24%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.68%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight19.42%

1M Return4.00%

Is VTVT undervalued or overvalued?

VTVT scores 4.13/10 on fundamentals and holds a Fair valuation at present. Backed by its -68.52% ROE, 0.00% net margin, -6.01 P/E ratio, 2.52 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.